Despite encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from PBMs. Such companies are typically erecting limitations to reimbursement, including steep cost restrictions and prior autho